臨床眼科75巻12号

2021年11月発行

特集 網膜色素変性のアップデート

【治療法開発研究の最前線】

網膜色素変性に対する薬物治療の現在と未来

著者： 村上祐介¹

所属機関： ¹九州大学大学院医学研究院眼科学分野

ページ範囲：P.1498 - P.1504

文献概要

●網膜色素変性（RP）に共通する病態を標的として，神経保護，抗酸化，代謝修飾，抗炎症などの薬物治療が開発されている。

●酸化や炎症などのRPに伴う微小環境変化は，網膜局所のみならず末梢血を含めて全身性に起こっている。

●薬物治療の有効性はいまだ確立されていないものの，RP患者を対象とした臨床試験が日本を含む世界各国で実施されている。

参考文献

1）Frasson M, Sahel JA, Fabre M et al：Retinitis pigmentosa：rod photoreceptor rescue by a calcium-channel blocker in the rd mouse. Nat Med 5：1183-1187, 1999

2）Yamazaki H, Ohguro H, Maeda T et al：Preservation of retinal morphology and functions in royal college surgeons rat by nilvadipine, a Ca（2＋）antagonist. Invest Ophthalmol Vis Sci 43：919-926, 2002

3）Nakazawa M, Ohguro H, Takeuchi K et al：Effect of nilvadipine on central visual field in retinitis pigmentosa：a 30-month clinical trial. Ophthalmologica 225：120-126, 2011

4）Yamamoto S, Sugawara T, Murakami A et al：Topical isopropyl unoprostone for retinitis pigmentosa：microperimetric results of the phase 2 clinical study. Ophthalmol Ther 1：5, 2012

5）Komeima K, Rogers BS, Lu L et al：Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc Natl Acad Sci U S A 103：11300-11305, 2006

6）Murakami Y, Ikeda Y, Yoshida N et al：MutT homolog-1 attenuates oxidative DNA damage and delays photoreceptor cell death in inherited retinal degeneration. Am J Pathol 181：1378-1386, 2012

7）Martinez-Fernández de la Cámara C, Salom D, Sequedo MD et al：Altered antioxidant-oxidant status in the aqueous humor and peripheral blood of patients with retinitis pigmentosa. PLoS One 8：e74223, 2013

8）Campochiaro PA, Strauss RW, Lu L et al：Is there excess oxidative stress and damage in eyes of patients with retinitis pigmentosa? Antioxid Redox Signal 23：643-648, 2015

9）Ishizu M, Murakami Y, Fujiwara K et al：Relationships between serum antioxidant and oxidant statuses and visual function in retinitis pigmentosa. Invest Ophthalmol Vis Sci 60：4462-4468, 2019

10）Lee SY, Usui S, Zafar AB et al：N-acetylcysteine promotes long-term survival of cones in a model of retinitis pigmentosa. J Cell Physiol 226：1843-1849, 2011

11）Yoshida N, Ikeda Y, Notomi S et al：Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology 120：e5-e12, 2013

12）Campochiaro PA, Iftikhar M, Hafiz G et al：Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial. J Clin Invest 130：1527-1541, 2020

13）Chew EY, Clemons TE, Agrón E et al：Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration：AREDS report no. 35. Ophthalmology 120：1604-1611, 2013

14）Chew EY, Clemons TE, Agrón E et al：Effect of omega-3 fatty acids, Lutein/Zeaxanthin, or other nutrient supplementation on cognitive function：The AREDS2 Randomized Clinical Trial. JAMA 314：791-801, 2015

15）Christen WG, Glynn RJ, Sesso HD et al：Vitamins E and C and medical record-confirmed age-related macular degeneration in a randomized trial of male physicians. Ophthalmology 119：1642-1649, 2012

16）Berson EL, Rosner B, Sandberg MA et al：A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 111：761-772, 1993

17）Berson EL, Rosner B, Sandberg MA et al：ω-3 intake and visual acuity in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol 130：707-711, 2012

18）Hoffman DR, Hughbanks-Wheaton DK, Pearson NS et al：Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa（DHAX trial）：a randomized clinical trial. JAMA Ophthalmol 132：866-873, 2014

19）Hoffman DR, Hughbanks-Wheaton DK, Spencer R et al：Docosahexaenoic acid slows visual field progression in X-Linked retinitis pigmentosa：ancillary outcomes of the DHAX trial. Invest Ophthalmol Vis Sci 56：6646-6653, 2015

20）Berson EL, Rosner B, Sandberg MA et al：Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol 128：403-411, 2010

21）Rotenstreich Y, Belkin M, Sadetzki S et al：Treatment with 9-cis β-carotene-rich powder in patients with retinitis pigmentosa：a randomized crossover trial. JAMA Ophthalmol 131：985-992, 2013

22）Fortmann SP, Burda BU, Senger CA et al：Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer：an updated systematic evidence review for the U. S. Preventive Services Task Force. Ann Intern Med 159：824-834, 2013

23）Punzo C, Kornacker K, Cepko CL：Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa. Nat Neurosci 12：44-52, 2009

24）Aït-Ali N, Fridlich R, Millet-Puel G et al：Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis. Cell 161：817-832, 2015

25）Ikeda HO, Sasaoka N, Koike M et al：Novel VCP modulators mitigate major pathologies of rd10, a mouse model of retinitis pigmentosa. Sci Rep 4：5970, 2014

26）Nakano N, Ikeda HO, Hasegawa T et al：Neuroprotective effects of VCP modulators in mouse models of glaucoma. Heliyon 2：e00096, 2016

27）Hata M, Ikeda HO, Kikkawa C et al：KUS121, a VCP modulator, attenuates ischemic retinal cell death via suppressing endoplasmic reticulum stress. Sci Rep 7：44873, 2017

28）Hasegawa T, Ikeda HO, Iwai S et al：Branched chain amino acids attenuate major pathologies in mouse models of retinal degeneration and glaucoma. Heliyon 4：e00544, 2018

29）Ikeda HO, Muraoka Y, Hata M et al：Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion：An open-label, non-randomized, first-in-humans, phase 1/2 trial. PLoS One 15：e0229068, 2020

30）Herz J, Filiano AJ, Smith A et al：Myeloid cells in the central nervous system. Immunity 46：943-956, 2017

31）Karlstetter M, Scholz R, Rutar M et al：Retinal microglia：just bystander or target for therapy? Prog Retin Eye Res 45：30-57, 2015

32）Yoshida N, Ikeda Y, Notomi S et al：Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology 120：100-105, 2013

33）Murakami Y, Ikeda Y, Nakatake S et al：C-Reactive protein and progression of vision loss in retinitis pigmentosa. Acta Ophthalmol 96：e174-e179, 2018

34）Okita A, Murakami Y, Shimokawa S et al：Changes of serum inflammatory molecules and their relationships with visual function in retinitis pigmentosa. Invest Ophthalmol Vis Sci 61：30, 2020

35）Peng B, Xiao J, Wang K et al：Suppression of microglial activation is neuroprotective in a mouse model of human retinitis pigmentosa. J Neurosci 34：8139-8150, 2014

36）Terauchi R, Kohno H, Watanabe S et al：Minocycline decreases CCR2-positive monocytes in the retina and ameliorates photoreceptor degeneration in a mouse model of retinitis pigmentosa. PLoS One 16：e0239108, 2021